PhRMA Not a Fan of CMS Drug Price Negotiation Plans

Just as the US Centers for Medicare and Medicaid Services (CMS) closed its public comments for the initial draft guidance for its upcoming Medicare drug price negotiations process, the pharma industry group PhRMA has laid out its complaints in a 76-page letter delivered last week. The comment window, only one month long, was a sticking point for the group.

According to Rylee Wilson, “The association also called the proposed negotiation process a “black box,” and that the agency does not provide enough opportunities for drug manufacturers and external stakeholders to engage in the negotiation process.”

To read more, click here.

(Source: Becker’s Payer Issues, April 20^th, 2023)